Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824174 | 0.84 | PARP1 (0.60) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL501850 | 0.84 | PARP1 (0.60) | PARP1RAB9ANPC1TPMTTSHR | |
| SCHEMBL12865158 | 0.84 | PARP1 (0.60) | PARP1TPMTTSHRHTTAPOBEC3A | |
| SCHEMBL1006449 | 0.84 | PARP1 (0.60) | PARP1TSHRHTTAPOBEC3AAPOBEC3G | |
| SCHEMBL29547990 | 0.82 | TPMT (0.46) | RAB9ANPC1TPMTHTTKDR | |
| SCHEMBL7786069 | 0.82 | TPMT (0.46) | RAB9ANPC1TPMTHTTKDR | |
| SCHEMBL19723419 | 0.80 | HTT (0.46) | RAB9ANPC1TPMTHTTKDR | |
| SCHEMBL696914 | 0.80 | TPMT (0.70) | TPMTKDRSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL30762678 | 0.80 | TPMT (0.70) | TPMTKDRSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12876024 | 0.78 | SMN1; SMN2 (0.42) | RAB9ANPC1TPMTTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875151-B1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2023-09-20 | — | — | EP | disclosed |
| US-20230126391-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO[4.3.1] DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230126391-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO[4.3.1] DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-04-27 | — | — | US | disclosed |
| US-9914732-B2 | Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2018-03-13 | — | — | US | disclosed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | disclosed |
| EP-3097103-B1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-11-15 | — | — | EP | disclosed |
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V. (DE) | 2017-01-05 | — | — | US | disclosed |
| EP-3089969-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASES TYPE 1 AND TYPE 2 | Elexopharm GmbH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | disclosed |
| WO-2009100167-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100167-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009100168-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | HSD17B1, HSD17B2, HSD17B3 | PARP1 1850/4885RAB9A 4512/4885NPC1 1349/4885 |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | PARP1 3387/4885RAB9A 2065/4885NPC1 3319/4885 |
| US-20170002003-A1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | SNCA, DDT, DRD1 | PARP1 1592/4885RAB9A 2683/4885NPC1 140/4885 |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | PARP1 3337/4885RAB9A 2238/4885NPC1 2986/4885 |
| US-20230126391-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO[4.3.1] DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP8, FKBP2, FKBP1A | PARP1 3742/4885RAB9A 3625/4885NPC1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.